Literature DB >> 14671807

[Psychopharmacotherapy in advanced age].

G Adler1.   

Abstract

In recent years, psychopharmacotherapy in the elderly has been advanced by the introduction of newly developed drugs with high effectiveness and good tolerability. However, up to now these advances have not yet led to a broad change in the psychopharmacological treatment of elderly patients. Elderly patients with psychiatric disorders are frequently treated with older drugs, which have a high risk of side effects and drug interactions. The consequences are severe complications, such as falls or delirious episodes. In this article, general aspects of psychopharmacotherapy in the elderly will be briefly summarized. Special aspects of the treatment with antidepressants, antipsychotics, benzodiazepines, phase prophylactics and antidementives will be discussed in detail and recommendations for treatment will be given.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14671807     DOI: 10.1007/s00108-003-0938-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  23 in total

1.  Improving drug compliance after hospital discharge.

Authors:  E T MacDonald; J B MacDonald; M Phoenix
Journal:  Br Med J       Date:  1977-09-03

2.  Selective serotonin reuptake inhibitors (SSRIs) in the treatment of elderly depressed patients: a qualitative analysis of the literature on their efficacy and side-effects.

Authors:  J E Menting; A Honig; F R Verhey; M Hartmans; N Rozendaal; H C de Vet; H M van Praag
Journal:  Int Clin Psychopharmacol       Date:  1996-09       Impact factor: 1.659

Review 3.  Pharmacotherapy of late life mood disorders.

Authors:  N Herrmann; K E Bremner; C A Naranjo
Journal:  Clin Neurosci       Date:  1997

4.  Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study.

Authors:  S L Rogers; L T Friedhoff
Journal:  Eur Neuropsychopharmacol       Date:  1998-02       Impact factor: 4.600

5.  A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

Authors:  P N Tariot; P R Solomon; J C Morris; P Kershaw; S Lilienfeld; C Ding
Journal:  Neurology       Date:  2000-06-27       Impact factor: 9.910

6.  [Depression in the very elderly].

Authors:  M Linden; G Kurtz; M M Baltes; B Geiselmann; F R Lang; F M Reischies; H Helmchen
Journal:  Nervenarzt       Date:  1998-01       Impact factor: 1.214

7.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.

Authors:  M Rösler; R Anand; A Cicin-Sain; S Gauthier; Y Agid; P Dal-Bianco; H B Stähelin; R Hartman; M Gharabawi
Journal:  BMJ       Date:  1999-03-06

8.  A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients.

Authors:  O J Høyberg; B Maragakis; J Mullin; D Norum; E Stordall; P Ekdahl; E Ose; K M Moksnes; C Sennef
Journal:  Acta Psychiatr Scand       Date:  1996-03       Impact factor: 6.392

Review 9.  Recent pharmacologic advances in antidepressant therapy for the elderly.

Authors:  S H Preskorn
Journal:  Am J Med       Date:  1993-05-24       Impact factor: 4.965

Review 10.  Important drug-drug interactions in the elderly.

Authors:  R M Seymour; P A Routledge
Journal:  Drugs Aging       Date:  1998-06       Impact factor: 4.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.